
What Is GERD?
GERD stands for gastroesophageal reflux disease. The term describes a chronic condition where stomach contents move backward into the esophagus and produce bothersome symptoms or tissue damage.
The gastric balloon and gastric bypass both treat obesity, but they work in fundamentally different ways. The gastric balloon is a temporary, endoscopic device that fills part of the stomach for six to twelve months.

Explore more insights on treatments, recovery, and aesthetic care.
The gastric balloon and gastric bypass both treat obesity, but they work in fundamentally different ways. The gastric balloon is a temporary, endoscopic device that fills part of the stomach for six to twelve months. Gastric bypass is a permanent bariatric operation that rewires the digestive system, restricts intake, and reduces nutrient absorption (NIH Consensus Development Panel 1991). This article compares both treatments using peer-reviewed evidence, so you can understand the mechanism, expected results, risks, and candidacy criteria for each option before you speak with a specialist.
A gastric balloon is a temporary, endoscopic intervention. A bariatric surgeon performs no incisions. Gastric bypass is a permanent, anatomical operation that changes the stomach and small intestine.
A gastroenterologist places the intragastric balloon through the mouth during a brief endoscopy under sedation. The device stays in the stomach for a defined period and then a clinician removes it (Dumonceau 2008, 567). The body returns to its normal anatomy after removal.
A bariatric surgeon performs gastric bypass under general anesthesia. The operation creates a small gastric pouch, reroutes food past most of the stomach and the first part of the small intestine, and connects the pouch to the jejunum in a configuration called Roux-en-Y (Buchwald 2004, 1724). These changes stay in place for life.
The key distinction lies in duration and mechanism. The balloon acts as a reversible tool that supports a behavioral program. Gastric bypass acts as a metabolic intervention that changes how the body processes food permanently.
The balloon occupies roughly one third to one half of the stomach volume. This restriction slows gastric emptying and triggers early satiety, so patients eat less at each meal.
A clinician passes a deflated balloon through the esophagus during an upper endoscopy. The clinician fills the balloon with saline, usually 500 to 700 milliliters, and sometimes adds methylene blue to make a leak visible (Genco 2005, 1161).
The procedure takes about twenty to thirty minutes. The patient receives sedation, not general anesthesia. Most patients leave the endoscopy suite the same day.
The balloon compresses the upper stomach and activates stretch receptors that signal fullness to the brain.
This physical signal arrives earlier in a meal. Patients report reduced portion sizes and fewer urges to snack. The effect supports, but never replaces, dietary counseling and behavior change (ASGE Bariatric Endoscopy Task Force 2015, 1107).
Most balloons remain for six months. Some adjustable balloon systems stay for up to twelve months, depending on the device and the clinical protocol.
Balloon time limits exist because the stomach lining adapts. After prolonged contact, the risk of mucosal irritation, ulceration, and device-related complications rises, so a clinician must remove the balloon on schedule (American Society for Metabolic and Bariatric Surgery Clinical Issues Committee 2016, 464).
The stomach returns to its normal size and capacity. Hunger signals gradually normalize, so long-term weight control depends entirely on the habits the patient built during balloon therapy.
This transition explains why programs pair balloon treatment with structured nutrition support and behavioral therapy from day one. Without that foundation, the physiological driver of portion control disappears at removal.
Gastric bypass restricts how much food the stomach can hold, limits how many calories the body absorbs, and changes gut hormones that control appetite.
The surgeon divides the stomach and creates a pouch the size of an egg. This pouch holds only about 30 milliliters of food.
The surgeon then divides the small intestine and connects the distal segment, the Roux limb, to the new pouch. Food bypasses roughly 95 percent of the stomach, the duodenum, and part of the jejunum. Bile and digestive enzymes rejoin the food stream lower down (Buchwald 2004, 1725).
The small pouch forces smaller, slower meals. The bypassed segments absorb fewer calories, fat, and micronutrients.
The duodenum normally absorbs most iron, calcium, and certain B vitamins. After bypass, these nutrients move through altered anatomy, so the body absorbs less of them. This mechanism drives weight loss but also creates the need for lifelong supplementation (Mechanick 2020, 199).
Rerouted food changes gut hormone secretion. Levels of GLP-1 and PYY rise, while ghrelin falls. These shifts reduce hunger and improve glucose control before substantial weight loss even begins.
This hormonal action explains why gastric bypass resolves type 2 diabetes rapidly, often within days of surgery, independent of weight change (Schauer 2014, 2002).

Clinicians typically consider the balloon for adults with a body mass index between 30 and 40 who have not achieved results with diet and lifestyle alone.
The standard indication window is a BMI of 30 to 40. Some protocols accept a BMI of 27 or higher when the patient carries obesity-related conditions (American Society for Metabolic and Bariatric Surgery Clinical Issues Committee 2016, 462).
A clinician may use the balloon as a bridge. It reduces weight before a planned operation to shrink the liver and improve surgical safety, especially in patients with severe obesity.
A prospective study evaluated intragastric balloon placement precisely for this purpose in candidates awaiting laparoscopic gastric bypass with severe obesity, and it established this preoperative role in the research record (Kotzampassi 2011, 1525).
Clinicians exclude patients with large hiatal hernias, previous gastric surgery, active ulcers, bleeding disorders, and uncontrolled psychiatric conditions. All of these raise procedural risk or undermine treatment adherence (Dumonceau 2008, 568).
Gastric bypass suits adults with severe obesity who need durable, substantial weight loss and metabolic improvement.
The classic threshold is a BMI of 40 or higher, or a BMI of 35 or higher with a serious comorbidity (NIH Consensus Development Panel 1991, 957). Current guidelines also support consideration for patients with a BMI of 30 or higher who have metabolic disease (Garber 2016, 3).
Type 2 diabetes, obstructive sleep apnea, severe hypertension, and nonalcoholic fatty liver disease count among the conditions that strengthen the surgical indication.
Patients must stop smoking, tolerate anesthesia screening, commit to lifelong vitamin supplementation, and follow a structured follow-up program. Multidisciplinary teams assess each patient before they approve the operation (Mechanick 2020, 179).
Gastric bypass produces roughly two to three times more weight loss than the balloon, and it maintains that loss far longer (Buchwald 2004, 1724).
Patients typically lose 10 to 15 percent of total body weight over the six-month balloon period (ASGE Bariatric Endoscopy Task Force 2015, 1108). Results vary widely because the device only works alongside dietary change.
Patients lose 25 to 35 percent of total body weight within one to two years. Large prospective data confirm that most patients retain a significant portion of this loss at three years (Courcoulas 2013, 2418).
The balloon restricts volume alone. Gastric bypass restricts volume, reduces absorption, and shifts hunger hormones. Three simultaneous mechanisms outmatch one temporary mechanism.
Both treatments demand dietary discipline, but bypass provides a permanent anatomical safeguard. After balloon removal, maintenance rests entirely on the patient's habits (Sumithran 2011, 1597).
Gastric bypass delivers more durable results because its anatomical changes never expire.
Some weight regain is common because the stomach regains capacity. Ongoing counseling and activity habits determine how much weight returns.
The small pouch enforces portion control permanently. Hormonal adaptations also persist and continue to blunt appetite (Sjöström 2004, 2684).
High-calorie liquid foods, grazing behavior, untreated emotional eating, and missed follow-up visits all raise regain risk. Hormonal adaptations to weight loss also resist long-term maintenance, which is why structured support matters after either treatment (Sumithran 2011, 1602).
The balloon carries mainly short-term gastrointestinal side effects, plus rare serious complications. Bypass carries surgical risks and lifelong nutritional risks.
Nausea, vomiting, bloating, and stomach discomfort affect many patients during the first days after placement. These symptoms usually ease with medication and adaptation (Genco 2005, 1162). Serious complications such as balloon deflation with migration, hyperinflation, gastric obstruction, or pancreatitis are uncommon but well documented (American Society for Metabolic and Bariatric Surgery Clinical Issues Committee 2016, 465).
Early complications include anastomotic leak, bleeding, and infection. Later complications include marginal ulcers, strictures, internal hernias, dumping syndrome, and vitamin or mineral deficiencies (Mechanick 2020, 187).
Balloon risk peaks during the weeks after placement. Bypass risk splits into a perioperative phase and a lifelong metabolic phase. Each phase requires a different monitoring plan.
Any patient with persistent vomiting, severe abdominal pain, fever, black stools, or signs of dehydration should contact the care team immediately. These symptoms can signal a device complication or a surgical emergency.
Balloon recovery takes days. Bypass recovery takes weeks. Follow-up intensity runs higher after bypass.
Most patients resume normal activity within two to three days. Nausea management dominates the first week.
Hospital stays typically last one to three days. Patients progress from liquids to soft foods over several weeks and return to full activity within four to six weeks.
Balloon care centers on nutritional counseling and symptom control. Bypass care adds bloodwork for vitamin levels, bone health monitoring, and medication adjustments for years (Mechanick 2020, 179).
Balloon patients return almost immediately. Bypass patients resume work within one to three weeks and strenuous exercise after clearance at six weeks.
Both treatments demand smaller, protein-first meals. Bypass adds mandatory lifelong supplementation.
Small, slow, protein-rich meals work best. Large meals trigger nausea, so patients learn portion discipline from day one.
Patients eat tiny, frequent meals for life. They must separate fluids from food, avoid high-sugar items to prevent dumping syndrome, and prioritize protein.
Balloon patients rarely need supplements beyond a standard multivitamin. Bypass patients require lifelong iron, calcium, vitamin D, and vitamin B12 at minimum (Mechanick 2020, 205).
Counseling drives success in both treatments. Evidence links structured support to better outcomes after every weight-loss intervention (American Society for Metabolic and Bariatric Surgery Clinical Issues Committee 2016, 466).
Yes. Surgery resolves or improves type 2 diabetes, hypertension, and cardiovascular risk far more consistently than balloon therapy.
In the STAMPEDE trial, gastric bypass pushed HbA1c below 6 percent in a far greater share of patients than intensive medical therapy alone (Schauer 2014, 2005). The metabolic benefit often appears within days of surgery (Mingrone 2012, 1581).
Sustained weight loss after bypass reduces blood pressure and medication needs. Long-term follow-up data show clearer benefit for surgically treated patients (Sjöström 2004, 2687).
Large cohorts show reduced cardiovascular events and lower mortality after bariatric surgery compared with non-surgical care (Adams 2007, 758).
The gastric balloon is less invasive by a wide margin.
The clinician accesses the stomach through the mouth. No incisions, no general anesthesia, and no anatomical alteration occur.
The operation requires general anesthesia, abdominal access, intestinal rerouting, and hospital admission.
A clinician removes the balloon and the anatomy resets. A surgeon can attempt bypass revision, but reversal is complex, uncommon, and never routine.
Costs vary by country and provider, but balloon treatment usually costs a fraction of gastric bypass.
Device type, program length, included counseling sessions, and clinic location drive the price.
Surgeon fees, hospital stay, anesthesia, and case complexity determine the total.
Budget for consultation and pre-treatment assessment, anesthesia and facility fees, follow-up visits, nutritional support, and supplements or long-term monitoring. Insurance often covers bariatric surgery that meets clinical criteria but excludes balloon therapy, so verify coverage before you decide.
Yes. Some programs use the balloon as a preoperative weight-reduction step.
Rapid preoperative loss shrinks a fatty liver, improves access to the upper stomach, and may reduce operative risk in patients with severe obesity.
In a prospective study of patients with severe obesity awaiting laparoscopic gastric bypass, balloon placement produced about 10 percent excess weight loss within three months, supporting its role as a bridge to surgery (Kotzampassi 2011, 1527).
Specialists consider it when operative risk runs high or when a patient needs structured support to commit to behavioral change before surgery.
No universal winner exists. The right choice matches your BMI, health profile, weight-loss goals, and willingness to accept surgery.
The balloon suits patients with moderate obesity who want a non-surgical, time-limited tool to jump-start lifestyle change.
Bypass suits patients with severe obesity or metabolic disease who need substantial, durable weight loss and accept permanent anatomical change.
Weigh BMI and obesity severity, existing medical conditions, previous weight-loss attempts, your desired degree of weight loss, willingness to undergo surgery, long-term lifestyle commitments, and your ability to maintain follow-up care.
Prepare targeted questions that turn general evidence into personal guidance.
Which treatment fits my BMI and health profile?
What weight-loss results are realistic for me?
What are my individual risks?
How long will treatment and recovery take?
What happens if I regain weight?
Will I need nutritional supplements?
Could a gastric balloon serve as a step toward bariatric surgery?
The table below summarizes the core comparison.
Factor | Gastric Balloon | Gastric Bypass |
Treatment type | Endoscopic | Surgical |
Abdominal surgery | No | Yes |
Anatomical alteration | No permanent alteration | Permanent gastrointestinal changes |
Treatment duration | Temporary, typically 6 months | Long-term, permanent |
Reversibility | Balloon can be removed | Reversal is complex and not routine |
Weight-loss potential | Generally more modest, 10–15% of body weight | Generally greater, 25–35% of body weight |
Nutrient absorption | Generally unchanged | Can be reduced |
Follow-up | Nutrition and lifestyle support | Long-term medical and nutritional monitoring |
Potential role | Weight-management intervention | Bariatric and metabolic surgery |
Base your decision on medical suitability, honest comparisons of benefit and risk, and your capacity for long-term change.
Evaluate expected benefits against potential risks. Compare short-term convenience against long-term outcomes. Commit to dietary and behavioral change before either treatment begins. Plan for ongoing medical monitoring, and treat individual obesity-related health risks as the deciding clinical factor, not marketing claims. A multidisciplinary team can match the evidence to your profile, and only that consultation converts general research into safe personal advice (American Society for Metabolic and Bariatric Surgery Clinical Issues Committee 2016, 467).
Adams, Ted D., et al. "Long-Term Mortality after Gastric Bypass Surgery." New England Journal of Medicine, vol. 357, no. 8, 2007, pp. 753–761.
American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. "Clinical Consensus Statement: Use of Intragastric Balloon for the Treatment of Obesity." Surgery for Obesity and Related Diseases, vol. 12, no. 3, 2016, pp. 462–467.
ASGE Bariatric Endoscopy Task Force, et al. "ASGE Position Statement on Endoscopic Bariatric Therapies." Gastrointestinal Endoscopy, vol. 81, no. 5, 2015, pp. 1107–1108.
Buchwald, Henry, et al. "Bariatric Surgery: A Systematic Review and Meta-Analysis." JAMA, vol. 292, no. 14, 2004, pp. 1724–1737.
Courcoulas, Anita P., et al. "Weight Change and Health Outcomes at 3 Years after Bariatric Surgery among Individuals with Severe Obesity." JAMA, vol. 310, no. 22, 2013, pp. 2416–2425.
Dumonceau, Jean-Marc, et al. "Intragastric Balloons: A Consensus Statement." Endoscopy, vol. 40, no. 6, 2008, pp. 567–570.
Garber, Alan J., et al. "American Association of Clinical Endocrinologists and American College of Endocrine Disease State Clinical Review: Clinical Practice Guidelines for Medical Care of Patients with Obesity." Endocrine Practice, vol. 22, suppl. 3, 2016, pp. 1–203.
Genco, Alfredo, et al. "BioEnterics Intragastric Balloon: The Italian Experience with 2,515 Patients." Obesity Surgery, vol. 15, no. 8, 2005, pp. 1161–1164.
Kotzampassi, K., et al. "Intragastric Balloon Preoperative Weight Reduction in Candidates for Laparoscopic Roux-en-Y Gastric Bypass: An Important and Necessary Step?" Obesity Surgery, vol. 21, no. 10, 2011, pp. 1525–1530.
Mechanick, Jeffrey I., et al. "Clinical Practice Guidelines for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Surgery Patient - 2019 Update." Surgery for Obesity and Related Diseases, vol. 16, no. 2, 2020, pp. 175–247.
Mingrone, Geltrude, et al. "Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes." New England Journal of Medicine, vol. 366, no. 17, 2012, pp. 1577–1585.
NIH Consensus Development Panel. "Gastrointestinal Surgery for Severe Obesity." Annals of Internal Medicine, vol. 115, no. 12, 1991, pp. 956–961.
Schauer, Philip R., et al. "Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 3-Year Outcomes." New England Journal of Medicine, vol. 370, no. 21, 2014, pp. 2002–2013.
Sjöström, Lars, et al. "Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery." New England Journal of Medicine, vol. 351, no. 26, 2004, pp. 2683–2693.
Sumithran, Priya, et al. "Long-Term Persistence of Hormonal Adaptations to Weight
Loss." New England Journal of Medicine, vol. 365, no. 17, 2011, pp. 1597–1604.